Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon/Chiron Myotrophin (IGF-1) shows 25% reduction in rate of ALS progression, company reports.

Executive Summary

CEPHALON/CHIRON MYOTROPHIN 8-POINT ALS SCORE DIFFERENCE FROM PLACEBO after nine months of therapy is significant in a Phase III study, Cephalon Senior-VP Michael Murphy, MD/PhD, reported June 10 at the World Federation of Neurology Committee on Motor Neuron Diseases in Talloires, France. Amyotrophic lateral sclerosis patients receiving the highest dose of Myotrophin (somatomedin-C) had an average 18-point increase from baseline on the Appel ALS scale compared to a 26-point increase for placebo-treated patients. A 20-point change indicates a major functional change in the ability of Lou Gehrig's disease patients to care for themselves.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel